All Specialties CardiologyNephrologyEndocrinologyPrimary CarePrescribing Information Previous Next What is the impact of SGLT2 inhibitor trials in HFpEF? FeaturingProfessor Andrew Coats | Australia Home List of Products HCPs All Specialties Shorts What is the impact of SGLT2 inhibitor trials in HFpEF? Related content Document ID: PC-ASK-100092 Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) The heart failure patient through a holistic lens (Full) Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) The heart failure patient through a holistic lens (Summary) Watch now Opens in new tab Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1) Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes? Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) The heart failure patient through a holistic lens (Full) Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) The heart failure patient through a holistic lens (Summary) Watch now Opens in new tab
Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1) Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes? Watch now Opens in new tab